Intramedullary spinal cord implantation of human CD34(+) umbilical cord-derived cells in ALS. Amyotroph Lateral Scler

Departments of Neurology , Hannover , Germany.
Amyotrophic Lateral Sclerosis (Impact Factor: 2.37). 08/2011; 12(5):325-30. DOI: 10.3109/17482968.2011.580850
Source: PubMed


Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder with marginal therapeutic options. Degeneration of motor neurons in the primary motor cortex, brainstem and spinal cord lead to rapidly progressive paralysis and finally to death due to respiratory failure. As pharmacological therapies have failed to provide sufficient neuroprotective effects in ALS, transplantation of stem or progenitor cells is considered a promising treatment strategy. Cell transplantation approaches in ALS mainly aim to generate a neuroprotective environment for degenerating motor neurons by transplantation of non-neuronal cells, rather than to replace lost motor neurons. We present a 63-year-old male patient suffering from ALS who underwent intramedullary thoracic spinal cord implantation of human CD34(+) umbilical cord-derived haematopoietic progenitor cells with a three-year follow up after transplantation.

Download full-text


Available from: Eva M Weissinger, Feb 09, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Administration of stem cells is a promising novel approach for treatment of neurodegenerative diseases. For in vivo monitoring of transplanted cells, non-invasive imaging modalities are needed. In this study we determined the tracking efficiency of a superparamagnetic iron oxide (SPIO)-labelled canine cell line (MTH53A) in vitro as well as the human CD34(+) umbilical cord blood stem cells (hUCBCs) in vitro and in vivo efficiency by magnetic resonance imaging (MRI). SPIO-labelled MTH53A cells and hUCBCs were scanned in agar gel phantoms at 1.0 T or 7.0 T. For in vivo detection, 100,000 labelled hUCBCs were injected into the spinal cord of a transgenic amyotrophic lateral sclerosis (ALS) mouse and scanned at 7.0 T. In vitro, 100,000 MTH53A cells and 250,000 hUCBCs were visible at 1.0 T. Scanning with 7.0 T revealed 25,000 detectable MTH53A cells. In vivo, 7.0 T MRI showed clear signals of 100,000 implanted cells. MRI combined with SPIO nanoparticles provides valuable potential for non-invasive, non-toxic in vivo tracking of cells implanted into the spinal cord.
    In vivo (Athens, Greece) 01/2012; 26(1):31-8. · 0.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) and other cellular therapies are a promising alternative in the treatment of neurodegenerative diseases. Preclinical data suggests that MSCs may have therapeutic potential for ALS, a lethal neurodegenerative disease involving a rapidly progressive death of motor neurons. However, the positive results of cell therapy in animal models have not been con fi rmed by the phase I/II clinical trials performed to date. The results from patients’ off-label cell treatments in clinics worldwide, which are the majority of cases, have also failed to provide grounds for optimism. We reviewed the clinical trials published to date, and social networking tools giving details of ALS patients’ experiences with off-label cell treatments. There is no objective evidence that MSC therapy can halt or slow down the course of the disease. This conclusion is supported by a recent metaanalysis of a larger series with intraspinal administration, with a 9-year follow-up, which detected no clear clinical bene fi ts. Future trials should be regulated by an international consortium of stem cell networks to ensure regulatory oversight of these modern therapies.
    2ond Edition edited by Lucas G. Chase & Mohan C. Vemuri, 12/2012; Springer New York Heidelberg Dordrecht London., ISBN: ISBN 978-1-62703-199-8 ISBN 978-1-62703-200-1 (eBook
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nearly 1.5 million people in the US live with a spinal cord injury (SCI). The cost to the health system is estimated at over $10billion annually likely because over 65% of SCIs occur at the cervical level. Despite medical advances, many SCI patients still experience substantial neurological disability and high dependency with severe loss of motor, sensory and autonomic function. The consensus from a combination of in vitro studies and in vivo models is that mesenchymal or stromal cells, and possibly even neural progenitors, regardless of derivation act through the provision of trophic support and inflammatory modulation. Indeed, they have been found to secrete a wide spectrum of diffusible factors with known roles in both. As such, mesenchymal cells, obtainable from multiple tissues, are ideally suited to addressing many pathophysiological consequences of SCI. Advances in understanding the latter, structural and functional magnetic resonance imaging, image-guided microneurosurgical techniques and transplantable cell biology have enabled the clinical use of cell-based therapies. Of the twenty most recent cell therapy clinical trials for SCI, seven involve adult bone marrow mesenchymal cells and six others umbilical cord cells. This reflects the growing recognition of the clinical potential of perinatal cells. However, a limited understanding of how best to exploit the capabilities of these cells impedes a full-scale clinical deployment. This mini-review focuses on recent developments that are likely to facilitate the targeted application of these cells to treat specific secondary pathophysiological processes.
    Current Stem Cell Research & Therapy 12/2012; 8(1). DOI:10.2174/1574888X11308010005 · 2.21 Impact Factor
Show more